vs
Apellis Pharmaceuticals, Inc.（APLS）与亿咖通科技（ECX）财务数据对比。点击上方公司名可切换其他公司
亿咖通科技的季度营收约是Apellis Pharmaceuticals, Inc.的1.6倍（$323.3M vs $199.9M），亿咖通科技净利率更高（-21.4% vs -29.5%，领先8.1%），亿咖通科技同比增速更快（6.5% vs -5.9%），Apellis Pharmaceuticals, Inc.自由现金流更多（$-14.3M vs $-86.5M）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
亿咖通科技是全球化出行科技企业，核心业务涵盖智能车载信息娱乐系统、高级驾驶辅助技术、车联网云服务开发，为全球多家车企提供一站式智能汽车解决方案，在中国及欧洲市场拥有成熟布局。
APLS vs ECX — 直观对比
营收规模更大
ECX
是对方的1.6倍
$199.9M
营收增速更快
ECX
高出12.4%
-5.9%
净利率更高
ECX
高出8.1%
-29.5%
自由现金流更多
APLS
多$72.2M
$-86.5M
损益表 — Q4 FY2025 vs Q2 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $323.3M |
| 净利润 | $-59.0M | $-69.1M |
| 毛利率 | — | 15.5% |
| 营业利润率 | -25.6% | -20.2% |
| 净利率 | -29.5% | -21.4% |
| 营收同比 | -5.9% | 6.5% |
| 净利润同比 | -62.2% | 12.8% |
| 每股收益（稀释后） | $-0.40 | $-0.20 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收APLSECX
| Q4 25 | $199.9M | — | ||
| Q3 25 | $458.6M | — | ||
| Q2 25 | $178.5M | $323.3M | ||
| Q1 25 | $166.8M | — | ||
| Q4 24 | $212.5M | — | ||
| Q3 24 | $196.8M | — | ||
| Q2 24 | $199.7M | $303.5M | ||
| Q1 24 | $172.3M | — |
净利润APLSECX
| Q4 25 | $-59.0M | — | ||
| Q3 25 | $215.7M | — | ||
| Q2 25 | $-42.2M | $-69.1M | ||
| Q1 25 | $-92.2M | — | ||
| Q4 24 | $-36.4M | — | ||
| Q3 24 | $-57.4M | — | ||
| Q2 24 | $-37.7M | $-79.2M | ||
| Q1 24 | $-66.4M | — |
毛利率APLSECX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 15.5% | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 22.6% | ||
| Q1 24 | — | — |
营业利润率APLSECX
| Q4 25 | -25.6% | — | ||
| Q3 25 | 48.7% | — | ||
| Q2 25 | -18.6% | -20.2% | ||
| Q1 25 | -50.0% | — | ||
| Q4 24 | -12.3% | — | ||
| Q3 24 | -24.0% | — | ||
| Q2 24 | -14.7% | -22.2% | ||
| Q1 24 | -36.0% | — |
净利率APLSECX
| Q4 25 | -29.5% | — | ||
| Q3 25 | 47.0% | — | ||
| Q2 25 | -23.6% | -21.4% | ||
| Q1 25 | -55.3% | — | ||
| Q4 24 | -17.1% | — | ||
| Q3 24 | -29.2% | — | ||
| Q2 24 | -18.9% | -26.1% | ||
| Q1 24 | -38.5% | — |
每股收益（稀释后）APLSECX
| Q4 25 | $-0.40 | — | ||
| Q3 25 | $1.67 | — | ||
| Q2 25 | $-0.33 | $-0.20 | ||
| Q1 25 | $-0.74 | — | ||
| Q4 24 | $-0.30 | — | ||
| Q3 24 | $-0.46 | — | ||
| Q2 24 | $-0.30 | $-0.23 | ||
| Q1 24 | $-0.54 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | $86.2M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $370.1M | $-293.7M |
| 总资产 | $1.1B | $494.9M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资APLSECX
| Q4 25 | $466.2M | — | ||
| Q3 25 | $479.2M | — | ||
| Q2 25 | $370.0M | $86.2M | ||
| Q1 25 | $358.4M | — | ||
| Q4 24 | $411.3M | — | ||
| Q3 24 | $396.9M | — | ||
| Q2 24 | $360.1M | $108.4M | ||
| Q1 24 | $325.9M | — |
总债务APLSECX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | $93.1M | — |
股东权益APLSECX
| Q4 25 | $370.1M | — | ||
| Q3 25 | $401.2M | — | ||
| Q2 25 | $156.3M | $-293.7M | ||
| Q1 25 | $164.2M | — | ||
| Q4 24 | $228.5M | — | ||
| Q3 24 | $237.1M | — | ||
| Q2 24 | $264.3M | $-198.5M | ||
| Q1 24 | $266.7M | — |
总资产APLSECX
| Q4 25 | $1.1B | — | ||
| Q3 25 | $1.1B | — | ||
| Q2 25 | $821.4M | $494.9M | ||
| Q1 25 | $807.3M | — | ||
| Q4 24 | $885.1M | — | ||
| Q3 24 | $901.9M | — | ||
| Q2 24 | $904.5M | $555.0M | ||
| Q1 24 | $831.9M | — |
负债/权益比APLSECX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.35× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | $-82.0M |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | $-86.5M |
| 自由现金流率自由现金流/营收 | -7.1% | -26.7% |
| 资本支出强度资本支出/营收 | 0.1% | 1.4% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $45.0M | — |
8季度趋势，按日历期对齐
经营现金流APLSECX
| Q4 25 | $-14.2M | — | ||
| Q3 25 | $108.5M | — | ||
| Q2 25 | $4.4M | $-82.0M | ||
| Q1 25 | $-53.4M | — | ||
| Q4 24 | $19.4M | — | ||
| Q3 24 | $34.1M | — | ||
| Q2 24 | $-8.3M | $-57.1M | ||
| Q1 24 | $-133.0M | — |
自由现金流APLSECX
| Q4 25 | $-14.3M | — | ||
| Q3 25 | $108.3M | — | ||
| Q2 25 | $4.4M | $-86.5M | ||
| Q1 25 | $-53.4M | — | ||
| Q4 24 | $19.3M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | $-8.4M | $-64.9M | ||
| Q1 24 | $-133.3M | — |
自由现金流率APLSECX
| Q4 25 | -7.1% | — | ||
| Q3 25 | 23.6% | — | ||
| Q2 25 | 2.5% | -26.7% | ||
| Q1 25 | -32.0% | — | ||
| Q4 24 | 9.1% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -4.2% | -21.4% | ||
| Q1 24 | -77.3% | — |
资本支出强度APLSECX
| Q4 25 | 0.1% | — | ||
| Q3 25 | 0.0% | — | ||
| Q2 25 | 0.0% | 1.4% | ||
| Q1 25 | 0.0% | — | ||
| Q4 24 | 0.0% | — | ||
| Q3 24 | 0.0% | — | ||
| Q2 24 | 0.0% | 2.6% | ||
| Q1 24 | 0.2% | — |
现金转化率APLSECX
| Q4 25 | — | — | ||
| Q3 25 | 0.50× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
ECX
暂无分部数据
